ArticleImmunology2026
Nbeal2 Inactivation Triggers Abl1 Stabilisation and Dysregulated Subcellular Localisation of the Multi-Drug-Resistant Protein MDR1 (ABCB1) in Mast Cells.
Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nbeal2 Inactivation Triggers Abl1 Stabilisation and Dysregulated Subcellular Localisation of the Multi-Drug-Resistant Protein MDR1 (ABCB1) in Mast Cells.Immunology · 2026Article
- TLR2 activation potentiates P-glycoprotein-mediated methotrexate efflux and enhances cytotoxicity of human NK cells against acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Inactivation of the BEACH (beige and chediak-higashi) family member NBEAL2 in humans and mice results in the development of the gray platelet syndrome (GPS), a bleeding disorder characterised by macrothrombocytopenia and splenomegaly. On the cellular level, NBEAL2 inactivation leads to functional defects in megakaryocytes, platelets, neutrophils and NK cells. In addition, Nbeal2 deletion in mice causes specific defects in mast cells (MCs), such as accumulation of transcription factors and proteins that are involved in the protein biosynthesis machinery. These defects culminate in non-physiological survival behaviour and an amplified stem cell factor (SCF)-, interleukin (IL)-3- and IL-33-induced cytokine production. Here we show that NBEAL2 deficiency also leads to an Abl1-supported increased surface expression of the multi-drug-resistant protein 1 (Mdr-1) ABCB1, which is antagonised by the IL-33-induced activation of the TAK1-IKK2 module and the activation of Src-family-kinases (SFKs). Our data demonstrate that NBEAL2 is required to control the surface expression of ABCB1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.